ライフサイエンスコーパス: fluid retention

1 betes, although their use remains limited by fluid retention.

2 t, but still exhibited rosiglitazone-induced fluid retention.

3 al role of ENaC in thiazolidinedione-induced fluid retention.

4 congestive heart failure due to TZD-related fluid retention.

5 eriority in the management of RSG-associated fluid retention.

6 owever, their use is complicated by systemic fluid retention.

7 ansport in the CD that underlies TZD-induced fluid retention.

8 cites, and seven of eight showed evidence of fluid retention.

9 nly thrombocytopenia, leukopenia, fever, and fluid retention.

10 ents and insulin users developed TZD-related fluid retention.

11 betic, non-TZD users with chronic HF who had fluid retention.

12 compared between TZD users with and without fluid retention.

13 No patients were taken off study because of fluid retention.

14 he utility of this regimen is not limited by fluid retention.

15 of troglitazone, which could in theory cause fluid retention.

16 cities were asthenia, flu-like symptoms, and fluid retention.

17 moderate in severity, and likely related to fluid retention.

18 Superficial edema (42% versus 15%) and fluid retention (45% versus 30%) were more prevalent wit

19 s include obesity, male sex, age, menopause, fluid retention, adenotonsillar hypertrophy, and smoking

20 We sought to define the characteristics of fluid retention after thiazolidinedione (TZD) initiation

21 Although fluid retention after treatment with TZD in diabetic pat

22 d anion secretion in pig jejunal tissue, and fluid retention and cGMP levels in STa-exposed loops.

23 PARgamma agonists, thiazolidinediones, cause fluid retention and edema due to unknown mechanisms.

24 ignificantly attenuated side effects such as fluid retention and heart weight gain associated with PP

25 upplemental oxygen are indicated in cases of fluid retention and hypoxemia, respectively.

26 tients with cirrhosis who had no evidence of fluid retention and in 20 pair-matched healthy control s

27 in the renal medulla where inhibition causes fluid retention and increased blood pressure.

28 3 to 4 adverse events; the most common were fluid retention and infection.

29 cation of beverages that promote longer-term fluid retention and maintenance of fluid balance is of r

30 tic capillaries, leading to 2.5-fold greater fluid retention and severe lymphedema after inflammation

31 No direct association between the risk of fluid retention and the baseline degree of severity of H

32 antidiabetic activity while not causing the fluid retention and weight gain that are serious side ef

33 d receptor gamma (PPARgamma) that can induce fluid retention and weight gain through unclear mechanis

34 proteinemia is significantly correlated with fluid retention and weight gain, development of ARDS and

35 Fatigue, fluid retention, and excessive tearing became more commo

36 Fatigue, fluid retention, and eye tearing/conjunctivitis became m

37 ain toxicities (> or = grade 2) were nausea, fluid retention, and fatigue, which occurred in 33%, 33%

38 resistance is associated with inflammation, fluid retention, and hyperparathyroidism.

39 higher plasma potassium concentration, more fluid retention, and significantly lower FE(K) and FE(Na

40 caused fatigue, gastrointestinal complaints, fluid retention, and thrombocytopenia in a number of pat

41 Hypoproteinemia, fluid retention, and weight gain are associated with dev

42 Neutropenia and fluid retention are dose-limiting.

43 s to reduce blood pressure, body weight, and fluid retention as well as to improve renal function.

44 Fluid retention associated with the use of TZD is common

45 Activation of this pathway mediates fluid retention associated with TZDs, and suggests amilo

46 In hemodialysis patients, greater fluid retention between 2 subsequent hemodialysis treatm

47 Such fluid retention can ultimately lead to pulmonary congest

48 the effects leading to increased adiposity, fluid retention, congestive heart failure, and bone frac

49 and tolerability issues such as weight gain, fluid retention, edema, congestive heart failure, and bo

50 to 424.5 mg/m2), 30 patients (81%) developed fluid retention, for which 11 (30%) subsequently stopped

51 ocorticoid-related adverse events, including fluid retention, hypertension, and hypokalemia, were mor

52 leak syndrome manifested by hypoalbuminemia, fluid retention, hypotension and, in one case, pulmonary

53 Vasopressin mediates fluid retention in heart failure.

54 We tested the hypothesis that salt and fluid retention in heart-transplant recipients (HTRs) is

55 al egress of albumin with subsequent osmotic fluid retention in some, but not all eyes.

56 e volume, which were attributed to excessive fluid retention in the anterior prostate and to expansio

57 was performed to determine the incidence of fluid retention in this cohort.

58 The mechanisms by which fluid retention influences cardiovascular survival in he

59 Fluid retention is an important consideration in the use

60 reported that the PPARgamma agonist-induced fluid retention is independent of ENaC activity.

61 These findings indicate that fluid retention is partly engendered by a failure to ref

62 reduce albuminuria in diabetic nephropathy, fluid retention limits their use.

63 understanding of the pathophysiology of the fluid retention may facilitate prevention.

64 nase inhibition mediate, to some extent, the fluid retention observed in patients treated with mixed

65 Oedema or fluid retention occurred in 67 (27%) patients given daru

66 rosis (31 [1%]), hypokalaemia (28 [1%]), and fluid retention or oedema (23 [1%]).

67 ents who required intensive care, had marked fluid retention, or were receiving intravenous vasodilat

68 heart rates, norepinephrine requirements and fluid retention (P </= .03).

69 mong the imatinib quartile categories except fluid retention, rash, myalgia, and anemia, which were m

70 Fluid retention related to TZD tends to be peripheral an

71 alizations are related to sodium (Na(+)) and fluid retention resulting from neurohumoral up-regulatio

72 In safety analyses, fluid retention, superficial edema, myalgia, vomiting, a

73 rimary end point was the incidence of severe fluid retention that necessitated treatment withdrawal.

74 , nausea, emesis, electrolyte imbalance, and fluid retention that were not dose limiting.

75 These effects were related to improved fluid retention using PEG-BSA-24 as evidenced by the sig

76 RGZ/FFB prevented the fluid retention usually associated with RGZ (-1.6 vs. 5.

77 he management of rosiglitazone (RSG)-induced fluid retention was evaluated in a multicenter, randomiz

78 Similar fluid retention was measured in mice with endothelial-re

79 Fluid retention was not observed and cutaneous toxicity

80 Severe fluid retention was rare (4% of patients).

81 um channel ENaC in thiazolidinedione-induced fluid retention, we used mice with conditionally inactiv

82 unique benefits are shadowed by the risk for fluid retention, weight gain, bone loss and congestive h

83 Physical signs of fluid retention were compared between TZD users and an a

84 Nineteen TZD users (17.1%) developed fluid retention, which reversed after drug withdrawal an

85 it lungs blocked sodium transport and caused fluid retention, which--together with patch-clamp and fl

86 However, OE2 may increase renal fluid retention within a physiological range of AVP.